Jaguar8 commented on a stock · Jul 18, 2024 20:31

NEWS

Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical Inc. (Nasdaq: MBOT) has completed the enrollment of clinical sites for its pivotal human clinical trial of the LIBERTY® Endovascular Robotic Surgical System. Memorial Sloan Kettering Cancer Center in New York City joins Brigham and Women's Hospital in Boston and Baptist Hospital of Miami as the third and final site. The trial is part of an Investigational Device Exemption (IDE) for LIBERTY®, with results expected to support future FDA marketing submission and commercialization.

Dr. Francois Cornelis, who will lead the trial at Memorial Sloan Kettering and serve as principal investigator for the overall LIBERTY clinical trial, expressed enthusiasm for the future of robotics in interventional procedures. Microbot Medical's CEO, Harel Gadot, highlighted the significance of partnering with a prestigious institution like Memorial Sloan Kettering Cancer Center.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

7045 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8164

Followers

Following

93K

Visitors